|
Post by mango on Aug 22, 2018 17:16:45 GMT -5
Yes, but do higher plasma levels translate into more effective control of PAH than what tyvaso achieves? That would have to be proven in a clinical trial and MNKD has indicated it wants to follow the 505(b)2 route to use tyvaso's efficacy data. Logic doesn’t require clinical trials.
|
|
|
Post by tomtabb on Aug 22, 2018 18:24:53 GMT -5
Yes, but do higher plasma levels translate into more effective control of PAH than what tyvaso achieves? That would have to be proven in a clinical trial and MNKD has indicated it wants to follow the 505(b)2 route to use tyvaso's efficacy data. Logic doesn’t require clinical trials. It's logical that if a higher concentration of the drug produces no more beneficial effect on on PAH than a lower concentration, then the patient simply doesn't need the higher concentration. Think in terms of drug receptors -- if there are only 50 receptors for the drug, then 50 of the drug will work fine, while 150 of the drug won't do anything more. Mannkind can't use tyvaso's 50 mcg dose data for 505(b)2 efficacy and then claim that a 150 mcg from a TS-trepostinil dose has a more beneficial effect. They would have to do some sort of trial to prove that claim.
|
|
|
Post by tinkusr8215 on Aug 22, 2018 18:28:39 GMT -5
Logic doesn’t require clinical trials. It's logical that if a higher concentration of the drug produces no more beneficial effect on on PAH than a lower concentration, then the patient simply doesn't need the higher concentration. Think in terms of drug receptors -- if there are only 50 receptors for the drug, then 50 of the drug will work fine, while 150 of the drug won't do anything more. Mannkind can't use tyvaso's 50 mcg dose data for 505(b)2 efficacy and then claim that a 150 mcg from a TS-trepostinil dose has a more beneficial effect. They would have to do some sort of trial to prove that claim. In this side of the world - logic is what prescribers use to rx a drug, patients use logic to use a drug , payors too use logic. no clinical trials. Every one is an armchair expert
so much logic aint it? or the simplest logic.
|
|
|
Post by tomtabb on Aug 22, 2018 18:36:03 GMT -5
It's logical that if a higher concentration of the drug produces no more beneficial effect on on PAH than a lower concentration, then the patient simply doesn't need the higher concentration. Think in terms of drug receptors -- if there are only 50 receptors for the drug, then 50 of the drug will work fine, while 150 of the drug won't do anything more. Mannkind can't use tyvaso's 50 mcg dose data for 505(b)2 efficacy and then claim that a 150 mcg from a TS-trepostinil dose has a more beneficial effect. They would have to do some sort of trial to prove that claim. In this side of the world - logic is what prescribers use to rx a drug, patients use logic to use a drug , payors too use logic. no clinical trials. Every one is an armchair expert
so much logic aint it? or the simplest logic. The logic is that if you take 50 mg of a blood pressure pill and that lowers your blood pressure to normal, then you don't need to take 100 or 150 mg.
|
|
|
Post by mnholdem on Aug 22, 2018 20:48:14 GMT -5
Tomtabb, are you ignorant or are you intentionally just trying to sound ignorant? Try doing a bit of research before you post your wild ass guesses. Please stop being so argumentative unless you have facts (and sources) to back up your conjectures.
Thank you!
|
|
|
Post by brotherm1 on Aug 22, 2018 23:23:41 GMT -5
👍
|
|
|
Post by jlaw277 on Oct 31, 2018 13:46:04 GMT -5
FWIW - Liquidia is now over 50% below it's high of $31.21 achieved on October 1. I have to believe that some of that is related to the completion of the MNKD/UTHR deal.
|
|
|
Post by agedhippie on Oct 31, 2018 15:19:43 GMT -5
FWIW - Liquidia is now over 50% below it's high of $31.21 achieved on October 1. I have to believe that some of that is related to the completion of the MNKD/UTHR deal. More likely it is just reverting to the launch price from August as everyone who made a quick buck on the spike exits.
|
|